Lung Cancer Clinical Trials in North Carolina

Showing 181-200 of 354 trials

High Dose Vitamin A Compound in Treating Participants With Resectable Non-Small Cell Lung Cancer

NCT03870529

This trial studies how well high dose vitamin A compound works in treating participants with non-small cell lung cancer that can be removed by surgery. Vitamin A compound may increase the number of germinal centers (immune centers that make antibodies mature) in tumor and lymph tissues which may be beneficial to patients with cancer.

Non Small Cell Lung CancerStage I Lung CancerStage Ib Lung Carcinoma+3 more

Wake Forest University Health Sciences20 participantsStarted Aug 2019

Winston-Salem, North Carolina, United States

COMPLETEDPHASE157 miles

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

NCT03219268

The primary goal of this Phase 1 study is to characterize the safety and tolerability of tebotelimab and establish the maximum tolerated dose (MTD) of tebotelimab in advanced solid tumors, and tebotelimab in combination with margetuximab in HER2+ advanced solid tumors. Pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD), and the anti-tumor activity of tebotelimab will also be assessed.

Advanced Solid TumorsHematologic NeoplasmsOvarian Cancer+7 more

MacroGenics277 participantsStarted Aug 2017

Gilbert, Arizona, United States • Los Angeles, California, United States • Los Angeles, California, United States +37 more locations

High Dose Vitamin A Compound in Treating Participants With Resectable Non-Small Cell Lung Cancer

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

Lung Cancer Trials in Other Cities

Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies

Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors

Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer

A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC

A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer

Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure

The Lung Screening, Tobacco and Health Project

A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors

A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors

A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab

Study of the CD40 Agonistic Monoclonal Antibody APX005M

Study of PF-07263689 in Participants With Selected Advanced Solid Tumors

A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy

Lung EpiCheck Biomarkers Development Study

Survival Prolongation by Rationale Innovative Genomics

Other Conditions in North Carolina